Chemically accessible hsp90 inhibitor that does not induce a heat shock response

ACS Medicinal Chemistry Letters

Volumn 5, Issue 7, 2014, Pages 771-776

  Koay, Yen Chin ^a   McConnell, Jeanette R ^a   Wang, Yao ^a   Kim, Seong Jong ^a   Buckton, Laura K ^a   Mansour, Flora ^a   McAlpine, Shelli R ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

conformation; heat shock protein 90; heat shock response; macrocycle; natural product; peptide; SM145; SM253

Indexed keywords

ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90 INHIBITOR; SM 145; SM 253; TANESPIMYCIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOMA CELL LINE; CELL DEATH; CELL SURVIVAL; COLON CARCINOMA; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; HEAT SHOCK RESPONSE; HUMAN; HYDROGEN BOND; IC 50; LIQUID CHROMATOGRAPHY; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FOLDING; STRUCTURE ACTIVITY RELATION; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING;

EID: 84904323079     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500114p     Document Type: Article

References (50)

1. Fierro-Monti, I.; Echeverria, P.; Racle, J.; Hernandez, C.; Picard, D.; Quadroni, M. Dynamic impacts of the inhibition of the molecular chaperone hsp90 on the T-cell proteome have implications for anti-cancer theapy PLoS One 2013, 8, e80425
2. Taipale, M.; Krykbaeva, I.; Koeva, M.; Kayatekin, C.; Westover, K. D.; Karras, G. I.; Lindquist, S. Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition Cell 2012, 150, 987-1001
3. Bohonowych, J. E.; Gopal, U.; Isaacs, J. S. Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls J. Oncol. 2010, 2010, 412-485
4. Takayama, S.; Reed, J. C.; Homma, S. Heat-shock proteins as regulators of apoptosis Oncogene 2003, 22, 9041-7
5. Neckers, L. Heat shock protein 90: the cancer chaperone J. Biosci. 2007, 32, 517-30
6. Neckers, L. Hsp90 inhbitors as novel cancer chemotherapeutic agents Trends Mol. Med. 2002, 8, S55-S61
7. Jolly, C.; Morimoto, R. I. Role of the heat shock protein response and molecular chaperones in oncogenesis and cell death J. Natl. Cancer Inst. 2000, 92, 1564-1572
8. Mayer, T. U.; Kapoor, T. M.; Haggarty, S. J.; King, R. W.; Schreiber, S. L.; Mitchison, T. J. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen Science 1999, 286, 971-974
9. Neckers, L.; Ivy, S. P. Heat shock protein 90 Curr. Opin. Oncol. 2003, 15, 419-424
10. Sarto, C.; Binz, P. A.; Mocarelli, P. Heat shock proteins in human cancer Electrophoresis 2000, 21, 1218-1226
11. Morimoto, R. I.; Kline, M. P.; Bimston, D. N.; Cotto, J. J. The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones Essays Biochem. 1997, 32, 17-29
12. Hartl, F. U.; Hayer-Hartl, M. Molecular chaperones in the cytosol: from nascent chain to folded protein Science 2002, 295, 1852-1858
13. Santagata, S.; Hu, R.; Lin, N. U.; Mendillo, M. L.; Collins, L. C.; Hankinson, S. E.; Schnitt, S. J.; Whitesell, L.; Tamimi, R. M.; Lindquist, S.; Ince, T. A. High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 18378-83
14. Mendillo, M. L.; Santagata, S.; Koeva, M.; Bell, G. W.; Hu, R.; Tamimi, R. M.; Fraenkel, E.; Ince, T. A.; Whitesell, L.; Lindquist, S. HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers Cell 2012, 150, 549-62
15. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; Burrows, F. J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors Nature 2003, 425, 407
16. Hsu, H. S.; Lin, J. H.; Huang, W. C.; Hsu, T. W.; Su, K.; Chiou, S. H.; Tsai, Y. T.; Hung, S. C. Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27 Cancer 2011, 117, 1516-28
17. Powers, M. V.; Workman, P. Inhibitors of the heat shock response: biology and pharmacology FEBS Lett. 2007, 581, 3758-69
18. Whitesell, L.; Bagatell, R.; Falsey, R. The stress response: implications for clinical development of hsp90 inhibitors Curr. Cancer Drug Targets 2003, 3, 349-358
19. Lamoureux, F.; Thomas, C.; Yin, M. J.; Kuruma, H.; Beraldi, E.; Fazli, L.; Zoubeidi, A.; Gleave, M. E. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer Cancer Res. 2011, 71, 5838-49
20. Zaarur, N.; Gabai, V. L.; Porco, J. A.; Calderwood, S.; Sherman, M. Y. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors Cancer Res. 2006, 66, 1783-91
21. Jhaveri, K.; Modi, S. HSP90 inhibitors for cancer therapy and overcoming drug resistance Adv. Pharmacol. 2012, 65, 471-517
22. Jhaveri, K.; Taldone, T.; Modi, S.; Chiosis, G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers Biochim. Biophys. Acta 2012, 1823, 742-55
23. http://www.clinicaltrials.gov.
24. Shelton, S. N.; Shawgo, M. E.; Matthews, S. B.; Lu, Y.; Donnelly, A. C.; Szabla, K.; Tanol, M.; Vielhauer, G. A.; Rajewski, R. A.; Matts, R. L.; Blagg, B. S. J.; Robertson, J. D. KU135, a Novel Novobiocin-Derived C-Terminal Inhibitor of the 90-kDa Heat Shock Protein, Exerts Potent Antiproliferative Effects in Human Leukemic Cells Mol. Pharmacol. 2009, 76, 1314-1322
25. Eskew, J. D.; Sadikot, T.; Morales, P.; Duren, A.; Dunwiddie, I.; Swink, M.; Zhang, X.; Hembruff, S.; Donnelly, A.; Rajewski, R. A.; Blad, B.; Manjarrez, J. R.; Matts, R. L.; Holzbeierlein, J. M.; Vielhauer, G. A. Development and characeterizatrion of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells BMC Cancer 2011, 11, 468
26. McConnell, J. R.; Alexander, L. D.; McAlpine, S. R. A heat shock protein inhibitor that modulates immunophilins and regulates hormone receptors Bioorg. Med. Chem. Lett. 2014, 24, 661-666
27. Davis, M. R.; Singh, E. K.; Wahyudi, H.; Alexander, L. D.; Kunicki, J.; Nazarova, L. A.; Fairweather, K. A.; Giltrap, A. M.; Jolliffe, K. A.; McAlpine, S. R. Synthesis of Sansalvamide A peptiodmimetics: trizaole, oxazole, thiazole, and psuedoproline containing compounds Tetrahedron 2012, 68, 1029-1051
28. Ardi, V. C.; Alexander, L. D.; Johnson, V. A.; McAlpine, S. R. Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins ACS Chem. Biol. 2011, 6, 1357-1367
29. Vasko, R. C.; Rodriguez, R. A.; Cunningham, C. N.; Ardi, V. C.; Agard, D. A.; McAlpine, S. R. Mechanistic studies of Sansalvamide A-Amide: an allosteric modulator of Hsp90 ACS Med. Chem. Lett. 2010, 1, 4-8
30. Sellers, R. P.; Alexander, L. D.; Johnson, V. A.; Lin, C.-C.; Savage, J.; Corral, R.; Moss, J.; Slugocki, T. S.; Singh, E. K.; Davis, M. R.; Ravula, S.; Spicer, J. E.; Oelrich, J. L.; Thornquist, A.; Pan, C.-M.; McAlpine, S. R. A third generation of Sansalvamide A derivatives: Design and synthesis of Hsp90 Inhibitors Bioorg. Med. Chem. 2010, 18, 6822-6856
31. Otrubova, K.; Lushington, G. H.; Vander Velde, D.; McGuire, K. L.; McAlpine, S. R. A comprehensive study of Sansalvamide A derivatives and their structure-activity relationships against drug-resistant colon cancer cell lines J. Med. Chem. 2008, 51, 530-544
32. Rodriguez, R. A.; Pan, P.-S.; Pan, C.-M.; Ravula, S.; Lapera, S. A.; Singh, E. K.; Styers, T. J.; Brown, J. D.; Cajica, J.; Parry, E.; Otrubova, K.; McAlpine, S. R. Synthesis of second generation Sansalvamide A derivatives: Novel templates as potent anti-tumor agents J. Org. Chem. 2007, 72, 1980-2002
33. Pan, P. S.; McGuire, K.; McAlpine, S. R. Indentification of compounds potent against pancreatic cancers Bioorg. Med. Chem. Lett. 2007, 17, 5072-5077
34. Styers, T. J.; Kekec, A.; Rodriguez, R. A.; Brown, J. D.; Cajica, J.; Pan, P.-S.; Parry, E.; Carroll, C. L.; Medina, I.; Corral, R.; Lapera, S.; Otrubova, K.; Pan, C.-M.; McGuire, K. L.; McAlpine, S. R. Synthesis of Sansalvamide A derivatives and their cytotoxicity in the colon cancer cell line HT-29 Bioorg. Med. Chem. 2006, 14, 5625-5631
35. Otrubova, K.; Styers, T. J.; Pan, P.-S.; Rodriguez, R.; McGuire, K. L.; McAlpine, S. R. Synthesis and novel structure-activity relationships of potent Sansalvamide A derivatives Chem. Commun. 2006, 1033-1034
36. Kunicki, J. B.; Petersen, M. N.; Alexander, L. D.; Ardi, V. C.; McConnell, J. R.; McAlpine, S. R. Synthesis and evaluation of biotinylated Sansalvamide A analogs and their modulation of Hsp90 Bioorg. Med. Chem. Lett. 2011, 21, 4716-4719
37. Styers, T. J.; Rodriguez, R. A.; Pan, P.-S.; McAlpine, S. R. High-yielding macrocyclization conditions used in the synthesis of novel Sansalvamide A derivatives Tetrahedron Lett. 2006, 47, 515-517
38. Sydor, J. R.; Normant, E.; Pien, C. S.; Porter, J. R.; Ge, J.; Grenier, L.; Pak, R. H.; Ali, J. A.; Dembski, M. S.; Hudak, J.; Patterson, J.; Penders, C.; Pink, M.; Read, M. A.; Sang, J.; Woodward, C.; Zhang, Y.; Grayzel, D. S.; Wright, J.; Barrett, J. A.; Palombella, V. J.; Adams, J.; Tong, J. K. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90 Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 17408-17413
39. Porter, J. R.; Fritz, C. C.; Depew, K. M. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy Curr. Opin. Chem. Biol. 2010, 14, 412-420
40. Pan, P. S.; Vasko, R. C.; Lapera, S. A.; Johnson, V. A.; Sellers, R. P.; Lin, C.-C.; Pan, C.-M.; Davis, M. R.; Ardi, V. C.; McAlpine, S. R. A comprehensive study of Sansalvamide A derivatives: their structure-activity relationships and their binding mode to Hsp90 Bioorg. Med. Chem. 2009, 17, 5806-5825
41. Otrubova, K.; McGuire, K. L.; McAlpine, S. R. A scaffold targeting drug-resistant colon cancers J. Med. Chem. 2007, 50, 1999-2002
42. Wahyudi, H.; Wang, Y.; McAlpine, S. R. Utilizing a dimerization strategy to inhibit the dimer protein Hsp90: Synthesis and biological activity of a sansalvamide A dimer Org. Biomol. Chem. 2014, 12, 765-773
43. Kim, S. J.; Ramsey, D. M.; Boyer, C.; Davis, T.; McAlpine, S. R. Effectively delivering a drug using star polymers: Improving solubility of a unique hsp90 inhibitor ACS Med. Chem. Lett. 2013, 4, 915-920
44. Wahyudi, H.; Tantisantisom, W.; Liu, X.; Ramsey, D. M.; Singh, E. K.; McAlpine, S. R. Synthesis, structure-activity analysis, and biological evaluation of structurally related conformational isomers J. Org. Chem. 2012, 77, 10596-10616
45. Ramsey, D. M.; McConnell, J. R.; Alexander, L. D.; Tanaka, K. W.; Vera, C. M.; Mcalpine, S. R. A new Hsp90 inhibitorthat exhibits a novel biological profile Bioorg. Med. Chem. Lett. 2012, 22, 3287-3290
46. Schmacher, R. J.; Hansen, W. J.; Freeman, B. C.; Alnemri, E.; Litwack, G.; Toft, D. O. Cooperative action of Hsp70, Hsp90, and DnaJ proteins in protein renaturation Biochemistry 1996, 35, 148-149
47. Wilsen, S.; Gestwicki, J. E. Identification of small molecules that modify the protein folding activity of heat shock protein 70 (Hsp70) Anal. Biochem. 2008, 374, 371-376
48. Wei, L.; Liu, T.; Wang, H.; Hong, H.; Yu, A.; Feng, H.; Chang, W. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial mesenchymal transition and nuclear factor-kB Breast Cancer Res. 2011, 13, R101
49. Mitra, A.; Shevde, L. A.; Samant, R. S. Multi-faceted role of HSP40 in cancer Clin. Exp. Metastasis 2009, 26, 559-67
50. Heiferman, M. J.; Salabat, M. R.; Ujiki, M. B.; Strouch, M. J.; Cheon, E. C.; Silverman, R. B.; Bentrem, D. J. Sansalvamide induces pancreatic cancer growth arrest through changes in the cell cycle Anticancer Res. 2010, 30, 73-78